1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Mymetics Corporation

Mymetics Corporation

MYMX
Mymetics CorporationUS flagOther OTC
0.00
USD
- -
- -
46.00Market Cap
Mymetics Corporation
MYMX
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
5.99
0.68
1.52
2.2
1.54
- -
29.66
15.87
20.75
8.25
1.33
0.49
0.73
0.23
0.02
0.02
0.02
Revenue per Share
-71.91
-72.29
-104.08
-113.12
-91.94
-41.58
40.65
-21.54
-19.79
-39.27
-27.07
-27.47
-27.57
-27.38
-31.14
-31.64
-76.16
Basic EPS, GAAP
-49.47
-81.28
-114.3
-78.18
-45.82
-33.75
-12.88
19.34
4.67
-6.52
-6.52
-15.23
-6.64
-11.26
-11.25
-11.12
-11.44
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-297.99
-314.2
-412.16
-511.04
-538.58
-460.61
-417.59
-429.34
-447.05
-486.32
-513.39
-540.86
-568.43
-595.81
-626.95
-658.59
-728.78
Book Value per Share
-53.73
-97.06
-309.63
-323.28
-305.43
-271.51
-243.98
-258.21
-275.41
-299.25
-326.24
-353.55
-381.02
-408.37
-439.54
-471.21
-497.57
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
4
2
3
1
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-1,182.28
-9,749.23
-5,446.31
-3,295.95
-1,658.52
- -
52.82
-23.22
-5.74
-83.32
-905.45
-2,025.33
-1,244.14
-4,497.14
-55,000
-58,166.67
-81,400
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-6
-7
-10
-11
-11
-6
6
-3
-3
-6
-4
-4
-4
-4
-5
-5
-12
Net Income, GAAP
- -
- -
- -
- -
- -
- -
0.79
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,200.59
-10,673.85
-6,836.24
-5,147.75
-5,988.07
- -
137.02
-135.72
-95.4
-475.98
-2,035.64
-5,562.67
-3,772.07
-11,880
-157,666.67
-160,166.67
-385,566.67
Profit Margin (%)
-4
- -
-4
-3
-6
-36
-36
-39
-42
-46
-50
-54
-58
-62
-67
-72
-75
Working Capital
- -
9
24
26
25
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-4
-9
-19
-21
-28
-33
-27
-30
-33
-39
-43
-47
-51
-55
-60
-65
-76
Total Equity
- -
- -
- -
- -
- -
- -
33.97
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-30.87
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-581.56
-627.57
-500.67
-255.16
242.11
-129.7
-118.81
-235.73
-162.53
-164.9
-165.49
-164.35
-186.96
-189.92
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
73
74
75
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
8
6
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
74
75
76
Payables & Accruals
1
1
1
ST Debt
73
74
75
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.36%
8.64%
8.01%
Free Cash Flow
- -
29.13%
-1.11%
Net Income, GAAP
-27.63%
3.3%
1.59%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-8.2
-7.26
-7.59
- -
-31.14
2022
-7.97
-8.84
-8.86
- -
-31.64
2023
-12.25
-50.6
-7.33
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Orthocell Limited (OCC.AX)
argenx SE (ARGX)
NightHawk Biosciences, Inc. (NHWK)
Itoco Inc. (ITMC)
Afyren Sas (ALAFY.PA)
Agenus Inc. (AGEN)
Business
Mymetics Corporation engages in the research and development of vaccines for infectious and life-disabling diseases, headquartered in Epalinges, Switzerland, and founded in 1990. The company specializes in virosome-based vaccine technology, utilizing lipid-based carriers that combine viral proteins and rationally designed antigens to induce protective mucosal immune responses. Mymetics' core product pipeline includes vaccine candidates targeting HIV-1/AIDS, Covid-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. It operates internationally with research activities notably in Switzerland and the Netherlands. Mymetics has established significant collaborations and strategic partnerships including agreements with the Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases, focusing on virosome-based malaria transmission-blocking vaccines. Additionally, the company collaborates with Sanofi Pasteur Biologics to evaluate the immunogenicity of influenza vaccines and has research engagements with MedImmune on RSV vaccines. Recently, Mymetics has progressed its Covid-19 vaccine development based on its virosome platform and maintains active joint research projects such as one with eTheRNA Immunotherapy on cancer immunotherapy. In the last two years, Mymetics has focused on advancing preclinical and clinical trials of its vaccine candidates, including early-stage HIV vaccine trials in Belgium and malaria vaccines in Tanzania. The company continues to expand its virosome vaccine portfolio and enhance its research capabilities, reflecting a strategic emphasis on innovative preventative vaccines for infectious diseases through cutting-edge virosome technology. Mymetics Corporation was formerly known as ICHOR Corporation before its name change in 2001 and remains headquartered in Switzerland with subsidiaries that support its R&D operations internationally.